ABCB1 (MDR1) polymorphisms and antidepressant response in geriatric depression

Area of Science:

• Pharmacogenetics
• Neuroscience
• Geriatric Medicine

Background:

• The ATP-binding cassette, subfamily B, member 1 (ABCB1) gene encodes P-glycoprotein, a transporter affecting drug distribution.
• ABCB1 genetic variations have been linked to varied responses to medications, including antidepressants.
• Predicting antidepressant response in geriatric patients is crucial for effective treatment.

Purpose of the Study:

• To investigate if ABCB1 gene polymorphisms predict antidepressant treatment response in elderly patients.
• To compare the effects of ABCB1 variation on paroxetine (a P-glycoprotein substrate) versus mirtazapine (not a P-glycoprotein substrate) response.

Main Methods:

• A clinical trial involving 246 elderly patients with major depression.
• Assessment of 15 single nucleotide polymorphisms (SNPs) in the ABCB1 gene.
• Comparison of treatment response to paroxetine and mirtazapine based on ABCB1 genotype.

Main Results:

• Two previously identified ABCB1 SNPs predicted time to remission in paroxetine-treated patients.
• These ABCB1 markers did not predict response in mirtazapine-treated patients.
• Results replicated previous findings, though statistical significance was not reached after Bonferroni correction.

Conclusions:

• Specific ABCB1 polymorphisms confirm their predictive value for antidepressant response to substrate medications in geriatric populations.
• ABCB1 genotyping may aid in personalizing antidepressant therapy for older adults.
• Further research is warranted to validate these pharmacogenetic markers.